Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: A randomized placebo‐controlled study

Norby, Gudrun E.; Holme, Ingar; Fellström, Bengt; Jardine, Alan G.; Cole, Edward; Abedini, Sadollah; Holdaas, Hallvard

doi:10.1002/art.24379

Cited by 50 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with SLE with and without end-stage renal failure are at increased risk of premature cardiovascular disease, and patients with SLE with transplants benefit from statin treatment 13. Our cohort had normal levels for atherogenic lipids, reflecting the extensive use of statins as part of our standard medication.…”

Section: Discussionmentioning

confidence: 91%

Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study

Norby

Strøm

Midtvedt

et al. 2010

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study

Norby

Strøm

Midtvedt

et al. 2010

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

show abstract

“…Recent studies demonstrate a reduction in cardiovascular risk with the administration of fluvastatin in patients with lupus recipients of kidney transplantation [43]. Two more patients died because of sepsis, probably related to immunosuppressive treatment.…”

Section: Discussionmentioning

confidence: 99%

Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre

Cairoli

Sánchez-Marcos

Espinosa

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Background. End-stage renal disease (ESRD) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Objectives. To analyze the outcome and prognostic factors of renal transplantation in patients with ESRD due to SLE from January 1986 to December 2013 in a single center. Results. Fifty renal transplantations were performed in 40 SLE patients (32 female (80%), mean age at transplantation 36 ± 10.4 years). The most frequent lupus nephropathy was type IV (72.2%). Graft failure occurred in a total of 15 (30%) transplantations and the causes of graft failure were chronic allograft nephropathy (n = 12), acute rejection (n = 2), and chronic humoral rejection (1). The death-censored graft survival rates were 93.9% at 1 year, 81.5% at 5 years, and 67.6% at the end of study. The presence of deceased donor allograft (P = 0.007) and positive anti-HCV antibodies (P = 0.001) negatively influence the survival of the renal transplant. The patient survival rate was 91.4% at the end of the study. Recurrence of lupus nephritis in renal allograft was observed in one patient. Conclusion. Renal transplantation is a good alternative for renal replacement therapy in patients with SLE. In our cohort, the presence of anti-HCV antibodies and the type of donor source were related to the development of graft failure.

show abstract

“…Fluvastatin decreased LDL by 29.2% and reduced cardiac events by 73.4% [141]. Two other intervention trials in patients with SLE measured surrogate imaging markers of CVD.…”

Section: Treatment and Management Recommendationsmentioning

confidence: 99%

Management of cardiovascular complications in systemic lupus erythematosus

Skamra¹,

Ramsey‐Goldman

2010

International Journal of Clinical Rheumatology

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Patients with SLE have an excess risk compared with the general population; this is particularly pronounced in younger women with SLE who have an excess risk of over 50-fold compared with population controls. There is a higher prevalence of subclinical atherosclerosis in patients with SLE compared with controls, as demonstrated by a variety of imaging modalities discussed in this review. The causality of the excess risk of CVD and subclinical atherosclerosis is multifactorial in patients with SLE. While traditional risk factors play a role, after controlling for the traditional Framingham risk factors, the excess risk is still 7.5-fold greater than the general population. This review will also cover novel cardiovascular risk factors and some SLEspecific variables that contribute to CVD risk. This review discusses the risk factor modification and the evidence available for treatment of these risk factors in SLE. There have not yet been any published randomized, controlled trials in patients with SLE with respect to CVD risk factor modifications. Thus, the treatment and management recommendations are based largely on published guidelines for other populations at high risk for CVD. Keywordscardiac imaging; cardiovascular disease; cardiovascular risk factors; subclinical atherosclerosis; systemic lupus erythematosusIn the last few decades, the prognosis of patients with systemic lupus erythematosus (SLE) has improved immensely. In the 1950s, the 5-year survival rate for SLE was approximately 50% according to a study performed in Toronto, Canada. Subsequent studies have found 5-year survival rates of 90% in patients with SLE [1]. A bimodal mortality pattern was first described in 1976 by Urowitz et al. in the Toronto Lupus cohort. Septicemia in the setting of high-dose prednisone was identified as an early cause of death in patients with more active SLE. Later in the disease course, death was associated with inactive SLE, long duration of prednisone therapy and myocardial infarction (MI) due to atherosclerotic heart disease [2]. More recent data from a large international cohort revealed a 60% decrease in the standardized all-cause mortality rates (SMR) from 1970-1979 (SMR: 4.9) to 1990. However, the SMR trend for cardiovascular disease (including heart disease, arterial disease and stroke) did not decline from 1970 to 2001 [3]. A Swedish cohort followed from 1964 to 1994 demonstrated similar findings of improved overall survival for patients with SLE over the last two decades, but the risk of cardiovascular death remained (by 1985-1994 NIH Public Access Author ManuscriptInt J Clin Rheumtol. Author manuscript; available in PMC 2010 December 1. Published in final edited form as:Int J Clin Rheumtol. This review will discuss the increased risk of CVD observed in patients with SLE, the role of traditional cardiovascular risk factors, the role of novel risk factors (some of which are lu...

show abstract

Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: A randomized placebo‐controlled study

Cited by 50 publications

References 15 publications

Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study

Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study

Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre

Management of cardiovascular complications in systemic lupus erythematosus

Contact Info

Product

Resources

About